click below
click below
Normal Size Small Size show me how
PHARMACOLOGY
Back to the Basics
Question | Answer |
---|---|
Changes in Absorption in Elderly | Increase of Gastric pH, decrease in absorptive surface area, decreased GI motility, delayed gastric emptying, decreased splanchnic blood flow |
Changes in Distribution in Elderly | Increased % of body fat & lean body mass. Decreased total body water, reduced concentration of serum albumin, decreased cardiac output |
Changes in Metabolism in Elderly | Rate of hepatic drug tens to decrease due to reduced hepatic blood flow, reduced liver mass, and decreased activity of some hepatic enzymes |
Changes in Excretion in Elderly | Decreased renal blood flow, decreased GFR, decreased tubular secretion, decreased number of nephrons |
If the drug contained is absorbed at the same rate and to the same extent | bioavailability |
Infants and young children are more susceptible to drugs because..... | immature organs |
Parenteral Administrations | IV, IM, SubQ, Intra/transdermal, lotions, eye/ear drops, inhalants |
Antagonist | Drug that binds to a receptor and blocks or inhibits their responses |
Agonist | Drug that binds to receptor and initiates or promotes the same response as the substance |
Generic Name | often classified with suffix of pharmacological class, easier to say and remember, only one (nonproprietary name) |
Brand Name | Manufacturers chosen name, how they are marketed, may have many (proprietary/trade name) |
Analgesic | Drugs that relieve pain without sedation |
Addiction | A condition of compulsive physiological need for use of habiting forming substances |
Withdrawal | Symptoms that occur after stopping an addicting substance, includes cravings for the substance |
Dependency | Physical and behavioral need to continue a drug, discontinuing leads to an abstinence syndrome |
Immunocompromised | Impaired or weakened immune system |
Percutaneous medications | medications introduced into the body through skin or muscous membranes (lotions, ointments, creams, inhalation, topical), or any med going through skin |
Enteral medications | Medications introduced into the body through GI tract (PO) |
Parenteral medications | Medications introduced directly into circulatory system (SubQ, IM, IV) |
Subtherapeutic level | inadequate therapeutic effect |
Supratherapeutic level | Excessive therapeutic effect |
Tolerance | state where medication loses effectiveness, higher doses are needed |
Half-life | The amount of time required to eliminate one half of the amount of a drug in the body |
Narrow therapeutic index | Drug relatively unsafe. |
Antipyretic | Drugs that lower body temperature |
Adrenergic | Drugs that stimulate the SNS either by direct activation or promoting release of receptor-activating catecholamines |
Pharmacokinetics | study of drug movement through the body |
Routes of Administration | enteral, parenteral, topical |
IV Absorption Barriers | bypassed |
IV Absorption Rate | Immediate |
IV Advantages | rapid onset, control, can administer large volumes of fluid, can administer irritants |
IV Disadvantages | irreversible, expensive, inconvenient, difficult, risk of fluid overload, infection, and clots, drug must be water soluble |
IM & SubQ Absorption Barriers | Through capillary Wall |
IM & SubQ Absorption Rate | Rapid with water-soluble drugs, slow with others |
IM & SubQ Advantages | Permits use of poorly soluble drugs and depot preparations |
IM & SubQ Disadvantages | can cause discomfort, inconvenient, potential for injury |
PO absorption barriers | epithelial lining of GI tract |
PO absorption rate | Slow, variable |
PO Advantages | easy, convenient, ideal for self-medication, potentially reversible |
PO Disadvantages | varies, inactivation of some drugs by gastric acid and digestive enzymes, possible nausea and vomiting from irritation, patient must be conscious and cooperative |
Absorption | movement of drug from site of administration into blood |
Factors effecting absorption | Rate of dissolution, surface area, drug flow, lipid solubility, pH |
Distribution | drug movement from the blood to the interstitial space of tissues and into cells |
Metabolism | biotransformation and is defined as the chemical alteration of a drug structure |
Excretion | process of drug removal from the body |
Sustained Release | capsules filled with tiny spheres that contain actual drug |
Enteric Coated | absorbed in small intestine, not in stomach to prevent GI upset and protect drug from gastric acid |
Body Composition | the same dose cannot be given to a smaller person as a bigger person |
Therapeutic Index | The measurement of drug safety. The drug level should fall in between the range. |
Controlled Substance Act Goals/Impact | reduce chances of drugs from legitimate sources being diverted to abusers, keep track of controlled substances, regulate drugs in categories of 1-5, place restrictions on prescriptions of schedule 2-5, schedule 2-4 must have a label stating it is against the law to transfer |
Schedule 2 Drugs | Highest potential for abuse, includes, codeine, fentanyl, hydrocodone, methadone, morphine, oxycodone, amphetamines, cocaine, barbiturates |
Schedule 1 drugs | have no medical use and includes meth, heroin |
Schedule 3 Drugs | cannabinoids, stimulants, barbiturates, anabolic steroids |
Schedule 4 Drugs | phentermine (stimulant), alprazolam (benzos) |
Schedule 5 Drugs | pregabalin, diphenoxylate plus atropine (voids) |
Idiosyncratic Effect | Uncommon |
paradoxical effect | opposite effect than intended |
Iatrogenic Disease | results from medical treatment |
Physical Dependence | body adapted to drug |
Carcinogenic Effect | ability of drugs and environmental chemicals to cause cancer |
teratogenic Effect | gross malformation |
Hepatotoxic | organ specific |
Toxicity | Adverse drug reaction caused by excessive dosing, and may occur even with normal dosing |
Allergic Reaction | immune response that intensity is based on the degree of sensitization of the immune system |